title: Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
abstract: The BCR-ABL transcript level (≤ 10%) at 3 months after tyrosine kinase inhibitors can predict long term outcome in the patients with chronic myeloid leukemia in chronic phase (CML-CP). However, the significance of transcript level was still not determined in different risk groups of patients. A total of 299 patients with CML-CP were enrolled and stratified according to prior interferon-α (IFN) treatment, age, and interval time between diagnosis and imatinib treatment to investigate the prediction value of BCR-ABL transcript level for overall survival (OS), event-free survival (EFS), progression-free survival (PFS). Univariate and multivariate analysis proved that BCR-ABL transcript level at 3 months were associated with the treatment outcome. However, in the patients with prior IFN treatment, younger age, and longer interval between diagnosis and IM treatment, the predictive value of transcript value remain obscure in terms of EFS, PFS and OS, respectively, as well as cumulative incidence of PCyR, CCR, MMR and CMR. In conclusion, the transcript level of BCR-ABL at 3 months could serve as a predictive parameter, but should be used with caution.
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China.
authors.forename: Xiu-Feng
authors.initials: XF
authors.lastname: Yin
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China; Department of Hematology, The Second Affiliated Hospital of Henan College of Traditional Chinese Medicine, No. 6 Dongfeng Road, Zhengzhou 450002, Henan, PR China.
authors.forename: Qiu-Ling
authors.initials: QL
authors.lastname: Ma
authors.affiliation: Ningbo First Hospital, Ningbo 315010, Zhejiang, PR China.
authors.forename: Qi-Tian
authors.initials: QT
authors.lastname: Mu
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China.
authors.forename: Li
authors.initials: L
authors.lastname: Shao
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China.
authors.forename: Sha-Sha
authors.initials: SS
authors.lastname: Wang
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China; Department of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, PR China.
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Meng
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China; Department of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, PR China.
authors.forename: Wei-Lai
authors.initials: WL
authors.lastname: Xu
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China; Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital, Zhejiang University School of Medicine, PR China.
authors.forename: Yun-Gui
authors.initials: YG
authors.lastname: Wang
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China; Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital, Zhejiang University School of Medicine, PR China.
authors.forename: Zhi-Mei
authors.initials: ZM
authors.lastname: Chen
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China.
authors.forename: Fei-Fei
authors.initials: FF
authors.lastname: Chen
authors.affiliation: Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, PR China; Department of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, PR China; Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital, Zhejiang University School of Medicine, PR China. Electronic address: zjuhematology@163.com.
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use; D002648:Child; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D016016:Proportional Hazards Models; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: BCR-ABL transcript; Chronic myeloid leukemia; Imatinib mesylate; Interferon-α; Prognostic value